Events

UK Bioscience Forum w/ Gareth Jones & Peju Oshisanya

Intellectual Property in AI and data technologies

11:45am | 14 October 2020

The competing demands of data creation, data protection and data provision and acquisition pull data IP practice in different ways. How can we manage these competing demands to produce a result that is ultimately most beneficial for patients and the sector?

Speakers:

  • Gareth Jones, VP Intellectual Property at BenevolentAI
  • Dr Nicola Baker-Munton, Chief Executive Officer at Statagem
  • Joe Foster, COO at Mogrify
  • Tim Hoctor, Vice President of Global Professional Services at Elsevier
  • Jule Sigall, Associate General Counsel, Open Innovation, IP Group at Microsoft

→ Register here

Diversity in data for drug discovery and clinical applications

11:45am | 14 October 2020

A lack of diversity in clinical datasets is a known problem for the life sciences industry, and one that must be addressed. In this session, we will discuss what different organisations are doing to address this, and share lessons they have learned from their experiences.

Speakers:

  • Peju Oshisanya MSc, BSc (HONS), Director, Clinical Programme Leader at BenevolentAI
  • Maria Chatzou Dunford, CEO and Co-Founder at Lifebit Biotech
  • Annette Jack, Founder at Egality
  • Dr Jason Mellad, CEO at Start Codon
  • Umang Patel, Clinical Director, Babylon

→ Register here


Peju Oshisanya

Clinical Drug Development Leader & Data Diversity Advocate at BenevolentAI

Peju is an innovative operational strategy expert with over 15 years wide-ranging experience relating to strategic programme leadership, planning and management of clinical trials with responsibility for global clinical programmes. She has extensive experience in working in early drug discovery and exploratory phases focused on the transition of early stage assets to clinical development. She has held leadership positions in programme management responsible for key clinical programmes and assets within Eli Lilly, Sanofi Aventis, Pfizer and Takeda. In her current role at BenevolentAI, she is responsible for driving the asset strategy to maximise the value of both early and late phase drug development programmes.

Gareth Jones

VP Intellectual Property

Gareth Jones is one of the the world's leading intellectual property strategists (IAM Strategy 300). At BenevolentAI he is responsible for IP activities including strategy, portfolio development, competitive intelligence, fundraising and M&A diligence, patent and data licensing, and collaborations. Gareth has worked at IBM, Vodafone, Microsoft, and also at tech startup SwiftKey where he built and scaled IP operations for one of the largest UK tech exits of 2015/2016


More Posts

You Might Also Like

Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021
Blog
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021